# NATCO: Generic drug approval for EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE

**Score:** 45/100

| Field | Value |
|---|---|
| Sponsor | NATCO |
| Product | EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE |
| Generic / ingredient | EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE |
| Approval | Generic drug approval (ANDA) |
| Application | ANDA214173 |
| Decided | 2026-08-26 |
| Panel / class | TABLET, ORAL |

## Why this score
- A generic launch.

Source: openFDA device PMA and Drugs@FDA endpoints (U.S. Food and Drug Administration) (https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214173). Last refreshed: 2026-11-04T06:06:18.796Z.
From openFDA (PMA and Drugs@FDA). openFDA can lag FDA decisions by days to weeks. Drug supplement types follow the FDA submission class (labeling and REMS, manufacturing/CMC, efficacy, other). Company and product level only. Verify on FDA databases before relying on an approval.